GlassScriptPhysician profile
Victor J Kabbany
NPI 1568623635
$3,316.10
in general payments reported to CMS, 2019-2025
25 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $256 · 2021: $265 · 2022: $359 · 2023: $694 · 2024: $717 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.61 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $519.65 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $493.83 | 2019-2025 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $476.07 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $339.84 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $323.34 | 2024-2025 | Ingrezza |
| Amgen INC. | $176.64 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $125.79 | 2019-2023 | Jynarque, Nuedexta |
| Janssen Pharmaceuticals, INC | $122.65 | 2019 | |
| Calliditas Therapeutics US INC. | $97.39 | 2022-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $92.79 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $92.38 | 2023-2025 | |
| Ardelyx, INC. | $68.05 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $65.74 | 2022-2023 | Trulicity, Mounjaro |
| Outset Medical INC | $47.59 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $44.02 | 2023 | Crysvita |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $34.12 | 2025 | Defencath |
| Nxstage Medical, INC. | $31.77 | 2022 | |
| Mallinckrodt Enterprises LLC | $28.62 | 2019 | |
| Lundbeck LLC | $25.39 | 2025 | Rexulti |
| Abbvie INC. | $23.63 | 2025 | |
| Travere Therapeutics, INC. | $22.63 | 2023 | |
| Fresenius USA Marketing, INC. | $21.91 | 2023 | Velphoro |
| Akebia Therapeutics INC | $16.07 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $13.46 | 2023 | Lupkynis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Kabbany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.